STERIS plc (Ireland) (STE) Stock forecasts
This article provides a brief overview of STERIS plc (STE), an Ireland-domiciled medical technology company specializing in sterilization services and infection prevention. It highlights an Argus report from November 18, 2026, which includes a current price of $254.76 for STE and offers access to a full report with a price target. The article also lists other related analyst reports for various companies.
McKesson Corporation (MCK) Stock Forecasts
Argus analyst David H. Toung has raised the target price for McKesson Corporation (MCK) stock, maintaining a "Buy" rating. The report, published on November 16, 2026, highlights McKesson's operations across North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical segments.
Gartner ranks healthcare supply chains, led by AdventHealth
Gartner's "Healthcare Supply Chain Top 25 for 2026" report named AdventHealth as the top performer for the third consecutive year, followed by Stanford Medicine, Bon Secours Mercy Health, Corewell Health, and Northwestern Medicine. The leading organizations excelled by accelerating clinical collaboration, strengthening supply chain resiliency, and advancing AI and digital capabilities. These strategies help maintain supply assurance during disruptions and improve day-to-day performance.
Henry Schein (HSIC) Launches BRIDGE Health Network, Is The 16% Undervaluation Convincing?
Henry Schein (HSIC) has launched the BRIDGE Health Network, an initiative aiming to integrate dental visits with broader preventive medical screenings. Despite recent short-term share price declines, the company shows positive longer-term returns and is considered 16% undervalued by analysts, with a fair value of $98.19. This valuation is supported by strong growth in high-margin segments and anticipated operating income savings, though execution risks remain.
Orthodontics Market to Reach USD 38.21 Billion by 2034 as Clear Aligners, Digital Workflows and Asia-Pacific Demand Reshape Care
The global orthodontics market, currently valued at USD 8.98 billion in 2025, is projected to reach USD 38.21 billion by 2034, growing at a CAGR of 17.45%. This significant expansion is driven by increasing adult and adolescent demand for aesthetic corrections, technological advancements like digital workflows, and wider distribution channels. While North America currently leads, the Asia-Pacific region is anticipated to be the fastest-growing market, with clear aligners and digital instruments fueling the market shift.
Morgan Stanley maintains Henry Schein at Underweight, raises price target to $68 from $64
Morgan Stanley has reiterated its "Underweight" rating on Henry Schein (HSIC) but increased its price target to $68 from $64, representing a 6.2% increase. This new price target suggests a potential downside of 20.0% from the stock's closing price of $84.96 on November 16. Investors can find more detailed analyst data and historical recommendations for Henry Schein on the Forecasts tab and News Flow sections of TradingView.
Henry Schein cuts FY2026 non-GAAP EPS guidance on accounting change
Henry Schein, Inc. (Nasdaq: HSIC) has revised its fiscal year 2026 non-GAAP diluted earnings per share guidance down to $5.42–$5.48 from $5.50–$5.56. This change is due to the company's new policy of excluding acquisition-related remeasurement gains from its non-GAAP financial results, effective with its fourth-quarter 2026 results. The company has also recast historical non-GAAP EPS and Adjusted EBITDA for 2024, 2025, and the first nine months of 2026 to ensure consistent comparison.
AHA, West Health announce collaboration with BD to increase innovation in hospitals and health systems
The American Hospital Association (AHA) and West Health Institute have partnered with Becton, Dickinson and Company (BD) to accelerate the adoption of innovative technologies in hospitals. The initiative will start with a cohort of 10 hospitals integrating advanced physiologic monitoring, with Vizient providing benchmarking and analytics. This collaboration aims to identify adoption barriers, refine implementation, and ultimately expand the model to improve patient outcomes and support care teams.
Dental equipment & technology stocks Q3 highlights: Dentsply Sirona
The dental equipment and technology sector reported a softer Q3, with revenues generally in line with analyst estimates but next quarter's guidance falling short. Dentsply Sirona (NASDAQ:XRAY) had the weakest performance, missing revenue and EPS estimates, while Envista Holdings (NVST) saw solid results despite a market downturn. Align Technology (ALGN) exceeded revenue expectations but offered disappointing guidance, and Henry Schein (HSIC) met expectations with strong revenue growth.
Henry Schein Updates Presentation of Non-GAAP Financial Measures
Henry Schein, Inc. (Nasdaq: HSIC) announced a change in its presentation of non-GAAP financial measures, effective with its fourth-quarter 2026 results. The company will now exclude acquisition-related remeasurement gains from non-GAAP results to better reflect underlying operating performance and improve comparability. This update has led to a revised FY2026 non-GAAP diluted EPS guidance of $5.42 to $5.48, down from the previous $5.50 to $5.56, solely due to this accounting change.
Form 8K Henry Schein Inc For: 16 November
This article announces the filing of Form 8K by Henry Schein Inc. for November 16. It includes various market data and related news but the core content is a brief notification of the regulatory filing.
Form 8K Henry Schein Inc For: 16 November By Investing.com
This article reports that Henry Schein Inc. filed a Form 8K on November 16, 2026. The brief report highlights the filing related to the company, identified by its stock symbol HSIC, which experienced a slight decline. No further details about the content of the 8K filing are provided.
Henry Schein Revises Non-GAAP EPS Guidance to $5.42–$5.48
Henry Schein (HSIC) has updated its non-GAAP EPS guidance for 2026 to $5.42–$5.48, down from the previous $5.50–$5.56. This revision is due to the company's decision to exclude acquisition-related remeasurement gains from its non-GAAP results, starting with the fourth quarter of 2026. This change aims to provide a more accurate reflection of underlying operating performance and does not impact reported GAAP results or the overall business outlook for 2026.
A health care supplier lowered its 2026 earnings forecast by 8 cents after changing how it counts acquisition gains.
Henry Schein, Inc. has updated its 2026 non-GAAP diluted EPS guidance to $5.42-$5.48, down from $5.50-$5.56, reflecting an $0.08 reduction. This change is solely due to a new policy of excluding acquisition-related remeasurement gains from non-GAAP financial results, which the company believes better reflects underlying operating performance. The voluntary change does not affect the company’s reported GAAP financial results or its underlying business outlook.
CareQuest and Henry Schein Launch BRIDGE Health Network
CareQuest Institute for Oral Health and Henry Schein, Inc. have launched the BRIDGE Health Network, an initiative aimed at integrating dental and medical care to improve whole-person health. The network will conduct pilot programs in diverse care settings, incorporating vital sign collection, lifestyle markers, and point-of-care screenings like HbA1c testing during routine dental hygiene visits. This effort seeks to expand preventive care, empower patients with comprehensive health summaries, and bridge care gaps between dental and medical providers.
Four entities report the same 5.51M-share passive stake in Henry Schein (HSIC).
Artisan Partners Asset Management Inc., Artisan Partners Holdings LP, Artisan Investments GP LLC, and Artisan Partners Limited Partnership have collectively reported a 4.8% passive stake in Henry Schein, Inc. (HSIC). Each of these four entities beneficially owns 5,505,566 common shares as of September 30, 2026. The filing indicates shared voting power over 4,971,331 shares and shared dispositive power over all 5,505,566 shares, with no sole voting or disposition authority reported by any of the parties.
CareQuest and Henry Schein Launch the BRIDGE Health Network to Advance Dental-Medical Integration
CareQuest Institute for Oral Health and Henry Schein, Inc. have announced the launch of the BRIDGE Health Network. This initiative will pilot health screenings, including A1C and vital sign checks, during routine dental hygiene visits to integrate dental and medical care. While there are no immediate financial terms or revenue impacts stated, the program aims to offer dental customers new preventive screening services and identify undiagnosed conditions like type 2 diabetes and prediabetes.
CareQuest and Henry Schein Launch the BRIDGE Health Network to Advance Dental-Medical Integration
CareQuest Institute for Oral Health and Henry Schein, Inc. have launched the BRIDGE Health Network, an initiative aimed at integrating dental and medical care. The network will pilot programs where dental professionals conduct systemic health screenings, including vitals and HbA1c tests, during routine dental hygiene visits. This effort seeks to improve early detection of conditions like prediabetes and diabetes, demonstrate the scalability of dental-medical integration, and ultimately enhance overall patient health outcomes.
80% of people with prediabetes don't know it. A dental network will pilot diabetes screening.
CareQuest Institute for Oral Health and Henry Schein, Inc. have launched the BRIDGE Health Network, an initiative to integrate dental and medical care. This network will pilot health screenings, including HbA1c tests for diabetes and prediabetes, during routine dental visits. The goal is to address the high percentage of individuals unaware of their prediabetes or diabetes conditions and improve overall health outcomes through early detection and integrated care.
Henry Schein (NASDAQ:HSIC) Q3 2026: EPS Beat, Guidance Raised
Henry Schein, Inc. (NASDAQ:HSIC) reported strong third-quarter 2026 results, with adjusted earnings per share exceeding analyst expectations and revenue aligning with forecasts. The company raised its full-year non-GAAP earnings guidance, attributing the profit growth to efficiency programs and a shift towards higher-margin specialty products and technology solutions. Despite modest top-line growth, cost management and a richer product mix have significantly boosted profitability.
A Nov. 17 webcast will feature a business update from Liquidia's leaders.
Liquidia Corporation announced that its CEO, Dr. Roger Jeffs, and COO/CFO, Michael Kaseta, will provide a business update at the 2026 Jefferies Global Healthcare Conference on November 17 in London. The presentation will be available via a webcast on Liquidia's investor website, with a replay accessible for at least 30 days. This update comes as Liquidia continues to develop and commercialize products for pulmonary hypertension and other respiratory and vascular diseases.
Cybercriminals Hit Two California Dental Practices
Two California dental practices, Santa Barbara Endodontics and Hollister Family Dental & Implant Center, along with Park Dental Partners in Minnesota, recently experienced data security incidents. Santa Barbara Endodontics suffered a ransomware attack impacting patient records, while Hollister Family Dental's third-party appointment system was breached. Park Dental Partners also reported unauthorized access to its network, potentially exposing patient health information.
Pet health spending remains ‘nonnegotiable’ priority, survey finds
A recent Elanco survey indicates that pet owners consider animal health spending a non-negotiable priority, even amid economic pressures, with 93% maintaining or increasing their spending. While medication purchases are shifting away from veterinary clinics to other retail channels, veterinarians' recommendations remain the primary influence on product selection. Future demand for pet ownership also appears strong, with 25% of current owners planning to adopt another pet within the next year.
Henry Schein, Inc. (HSIC) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for Henry Schein, Inc. (HSIC) on Yahoo Finance. It displays the average monthly price return for the company's stock from 2016 to 2026. The page also includes current stock information, related tickers, and market data.
Henry Schein to Present at Two Investor Conferences
Henry Schein, Inc. (Nasdaq: HSIC), a leading provider of healthcare solutions, announced it will present at two upcoming investor conferences. The presentations will take place in London on November 17, 2026, and in New York on December 1, 2026, and can be heard via live webcast. The company is a FORTUNE 500 company with sales of $13.2 billion in 2025.
McKesson beats Q2 estimates, raises full-year guidance
McKesson (NYSE:MCK) exceeded analyst expectations for its second-quarter earnings and revenue, reporting adjusted EPS of $11.68 and revenue of $111.0 billion. Despite these strong results, shares saw a slight dip of 0.8%. The pharmaceutical distributor also raised its fiscal 2027 adjusted earnings per share guidance, reflecting operational strength and strategic acquisitions.
Hims & Hers Health, RadNet, and Henry Schein shares are soaring, what you need to know
Shares of Hims & Hers Health, RadNet, and Henry Schein jumped after election results confirmed Democrats reclaimed majorities in Congress, easing regulatory uncertainty around drug pricing policy. Wall Street analysts project a strengthened recovery for the biopharmaceutical sector as existing government healthcare policies are expected to remain intact without new restrictions. Investors viewed the shifting balance of power as a stabilizing dynamic, leading to a rebound in broader equity markets.
Henry Schein Inc. stock underperforms Wednesday when compared to competitors despite daily gains
Henry Schein Inc. (HSIC) stock increased by 6.96% to $88.24 on Wednesday, during a strong trading session for the overall market, with the S&P 500 and Dow Jones Industrial Average also seeing significant gains. Despite this rise, the company's stock closed 4.27% below its 52-week high of $92.18, achieved on August 4th. The article notes that the stock underperformed compared to its competitors.
Tenet Healthcare Corporation stock hits all-time high at 285.71 USD
Tenet Healthcare Corporation (THC) stock has reached an all-time high of $285.71, reflecting strong performance and investor confidence. The company reported impressive third-quarter 2026 results, surpassing analyst expectations with adjusted EPS of $6.64 and revenue of $5.63 billion, and raised its full-year adjusted EBITDA outlook. Analysts from Mizuho and Guggenheim have maintained positive ratings and price targets, with InvestingPro analysis suggesting the stock remains undervalued.
Dentsply Sirona (XRAY) Q3 earnings report preview: what to look for
Dentsply Sirona (XRAY) is preparing to release its Q3 earnings report this Thursday afternoon. Analysts expect a 4.9% year-on-year revenue decline, consistent with the previous year, though the company generally beats Wall Street estimates. Peer results from Henry Schein and Align Technology offer some insight, and investor sentiment in the healthcare equipment and supplies segment has been positive, with Dentsply Sirona's stock up 14.1% in the last month.
Henry Schein Reports Q3 2026 Growth and Raises Full-Year Guidance
Henry Schein Inc. reported strong third-quarter 2026 results with $3.5 billion in sales, a 4.0% total growth, and an 8.6% increase in US dental merchandise sales. The company's GAAP net income rose by 26.2% year-over-year, and non-GAAP diluted EPS increased by 13.0%. Following these results, Henry Schein raised its full-year 2026 non-GAAP diluted EPS guidance to a range of $5.50 to $5.56, citing improved business performance and strategic growth initiatives.
Profit rises at Henry Schein (HSIC), but nine-month operating cash flow falls to $306M.
Henry Schein (HSIC) reported increased net income and diluted earnings per share for both the three and nine months ended September 26, 2026, compared to the prior-year periods. Quarterly net income rose to $119 million from $101 million, and nine-month net income increased to $320 million from $297 million. However, net cash provided by operating activities for the nine-month period decreased to $306 million from $331 million in the prior year.
Henry Schein Inc. stock underperforms Tuesday when compared to competitors
Shares of Henry Schein Inc. (HSIC) fell 4.76% to $82.50 on Tuesday, despite a mixed trading session where the S&P 500 Index rose. The stock closed 10.50% below its 52-week high of $92.18, achieved on August 4th. This performance saw Henry Schein Inc. underperform against its competitors.
Henry Schein Sees Pressure From Discretionary Dental Delays
Henry Schein Inc. (NASDAQ: HSIC) reported third-quarter earnings that surpassed estimates, with sales nearly in line with consensus. Despite strong U.S. dental merchandise sales and stable overall market conditions, the company faces pressure from delays in discretionary dental procedures due to patients being sensitive to out-of-pocket costs. Henry Schein raised its fiscal 2026 adjusted earnings guidance but reaffirmed its sales outlook.
Henry Schein FY26 Results: Adj EPS guidance raised to $5.50-$5.56
Henry Schein Inc. has raised its fiscal year 2026 adjusted earnings per share (EPS) guidance to $5.50-$5.56, exceeding analyst consensus and its previous forecast. The company maintained its sales outlook of $13.794 billion-$13.926 billion, indicating expected operational efficiencies or margin improvements driving higher profitability despite stable revenue projections. This revision highlights a more optimistic profitability outlook for the company.
Henry Schein Q3 2026 Earnings Call Transcript
Henry Schein (NASDAQ: HSIC) announced strong third-quarter 2026 financial results, including an 8.6% increase in U.S. dental merchandise sales and a 19.1% rise in adjusted non-GAAP diluted EPS. The company also expanded non-GAAP operating margins and repurchased $125 million in stock, raising its full-year 2026 financial guidance. Management expressed confidence in achieving double-digit earnings growth in 2027, driven by strategic initiatives focused on growth acceleration, operational simplification, and enhanced execution discipline.
HSIC Q3 Earnings Beat, Revenues Match, '26 EPS View Up, Stock Down
Henry Schein, Inc. (HSIC) reported strong third-quarter 2026 results, with adjusted earnings surpassing estimates and revenues matching expectations. The company saw internal sales growth across its distribution, specialty, and technology businesses, leading management to raise its 2026 adjusted earnings guidance. Despite the positive financial performance, HSIC's shares experienced a slight dip in pre-market trading.
A drug for eye melanoma showed a 57% eye-preservation rate in one trial group
IDEAYA Biosciences reported a widened net loss of $125.7 million in Q3 2026 but maintained its cash runway guidance into 2030. The company submitted its first FDA application for darovasertib plus crizotinib for metastatic uveal melanoma and presented positive clinical data, including a 57% eye preservation rate in a primary uveal melanoma trial. IDEAYA also detailed progress in its IDE849, IDE161, IDE034, IDE892, IDE397, and IDE574 pipeline programs, with several Phase 3 trials planned.
Henry Schein: Q3 Earnings Snapshot
Henry Schein Inc. (HSIC) reported strong third-quarter results, with net income of $119 million and adjusted earnings of $1.56 per share, surpassing analyst expectations. The health care products maker achieved revenue of $3.47 billion, matching Street forecasts, and provided a full-year earnings outlook.
McKesson (MCK) Q3 earnings report preview: what to look for
McKesson (NYSE: MCK), a healthcare distributor and services company, is set to report its Q3 earnings this Wednesday after market close. The market expects a 6.7% year-on-year revenue growth, a slowdown from the 10.1% increase in the same quarter last year, despite the company beating revenue expectations last quarter. Investors will be watching closely as analyst estimates have remained largely consistent, suggesting a steady performance is anticipated.
Henry Schein Inc. stock underperforms Monday when compared to competitors despite daily gains
Henry Schein Inc. (HSIC) stock increased by 2.05% on Monday, closing at $86.62, despite a mixed trading session for the broader market. The company's stock underperformed compared to some competitors and closed 6.03% below its 52-week high.
Form 424B2 Otis Worldwide Corp
Otis Worldwide Corporation is offering a new series of fixed-rate notes due in 20XX, with interest payable semi-annually beginning in 2027. The notes are unsecured, unsubordinated obligations and will rank equally with other unsecured debt. The net proceeds from this offering will primarily be used to repay the company's 2.293% Notes due April 5, 2027, and potentially other commercial paper borrowings for general corporate purposes.
How Investors May Respond To Align Technology (ALGN) Cautious Outlook And CEO Change
Align Technology (ALGN) recently reported Q3 2026 results and issued cautious Q4 and full-year guidance, alongside announcing a CEO transition to Jennifer L. Davis. This combination of higher year-on-year earnings, a conservative revenue outlook due to macro pressures, and new leadership from Procter & Gamble is prompting investors to scrutinize the company's execution and long-term strategy, particularly regarding margins and clear aligner penetration. Analysts anticipate mid-single-digit annual revenue expansion and higher earnings by the end of the decade, with the current valuation setup implying the market is already factoring in some uncertainty regarding the path to these projected profits.
Henry Schein Inc. stock outperforms competitors despite losses on the day
Shares of Henry Schein Inc. (HSIC) fell 1.80% on Friday to $84.88, despite the stock outperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also experienced declines during the trading session. This marks the end of a two-day winning streak for the stock.
Earnings Preview: Staar Surgical (STAA) Q3 Earnings Expected to Decline
Staar Surgical (STAA) is projected to experience a year-over-year decline in both earnings and revenues for the quarter ending September 2026, with an expected EPS of $0.19, down 58.7%, and revenues of $81.53 million, a 13.9% decrease. Despite a 20% upward revision in the consensus EPS estimate over the last 30 days, the company's Zacks Earnings ESP of -12.07% combined with a Zacks Rank #1 makes it difficult to definitively predict an earnings beat. Investors should monitor the actual results, expected on November 4, as they could significantly impact the stock's near-term performance.
American Public Education, Inc. Announces Appointment of Shira Goodman to Board of Directors
American Public Education, Inc. (APEI) has appointed Shira Goodman, former Staples CEO, to its board of directors. Goodman brings extensive executive leadership and corporate board experience to APEI, filling the vacancy left by James Kenigsberg, who is now the permanent Chief Innovation and Technology Officer. Goodman's expertise in growth and strategy will support APEI's mission of empowering students, while Kenigsberg will continue to lead technology transformation using AI and student-centered products.
American Public Education, Inc. Announces Appointment of Shira Goodman to Board of Directors
American Public Education, Inc. (APEI) has appointed Shira Goodman, former CEO of Staples, to its board of directors, bringing extensive leadership and governance expertise. Goodman fills the vacancy left by James Kenigsberg, who has permanently taken on the role of Chief Innovation and Technology Officer at APEI. Her appointment is expected to provide valuable perspective as the company focuses on growth and technology transformation to enhance educational experiences.
Henry Schein to Report Q3 Earnings: Here's What You Should Know
Henry Schein, Inc. (HSIC) is set to release its third-quarter 2026 earnings on November 3rd, with analysts expecting revenues of $3.47 billion and EPS of $1.34. The report will likely highlight strong performance in global distribution, specialty products, and technology segments, driven by solid demand and cloud-based solutions. While the company holds a Zacks Rank #3, its Earnings ESP of -0.10% suggests a lower chance of an earnings beat according to the Zacks model.
Henry Schein, Inc. Estimates – BOATS:HSIC
This page on TradingView provides financial estimates and actuals for Henry Schein, Inc. (HSIC), a medical distributor. Users can explore reported financial data and analyst estimates across various financial statements and valuation metrics, comparing actual results with average, high, and low estimates, and visualizing trends. The platform includes income statement, balance sheet, and cash flow data for both annual and quarterly periods.
Henry Schein Inc. stock underperforms Friday when compared to competitors
Shares of Henry Schein Inc. (HSIC) fell 1.21% to $84.96 on Friday, underperforming the broader market as the S&P 500 Index and Dow Jones Industrial Average also experienced declines. This drop ended a three-day winning streak for the stock.